Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 2Sarcoma 1Recurrence 1Peripheral Nervous System Diseases 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Malignant mesenchymal tumor 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Liposarcoma 1Hodgkin Disease 1Hemangiosarcoma 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Chondrosarcoma 1Breast Neoplasms 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × Glutamine × Clear all
NCT01157039 2016-02-24

A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin

AHS Cancer Control Alberta

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡